Tioconazole Gel Franchise in Ahmedabad

Antifungal Gel Supplier in Mumbai

Dermatology Gel Distributor in Delhi

Skin Care PCD Pharma Franchise in Bangalore

Tioconazole Gel Stockist in Hyderabad
Antifungal Gel Manufacturer & Exporter in Chandigarh

Home/Products /tioconazole-6-5-w-w-gel

Ticonole Gel

Composition : Tioconazole (6.5% w/w) Gel

Dosage Form : Gel

Packaging Type : Tube

Packaging : 30gm

Price : ₹0/-

Please Contact For Best Price

Ticonole Gel contains Tioconazole 6.5% w/w, a broad-spectrum antifungal agent used for the treatment of fungal skin infections. It is effective against dermatophytes and yeasts, helping relieve itching, redness, and irritation associated with fungal conditions.

Tioconazole works by disrupting fungal cell membrane synthesis, inhibiting the growth of fungi and leading to their elimination. This targeted action ensures effective clearance of infection and faster symptom relief.

This gel is commonly prescribed for tinea infections, candidal skin infections, and other superficial fungal conditions. Its topical gel formulation allows easy application, quick absorption, and localized action with minimal systemic exposure.

For PCD pharma franchise partners, Ticonole Gel is a high-demand dermatology product, available at the best price for PCD pharma franchise. Its strong prescriber confidence, consistent market demand, and wide usage in skin care make it a valuable addition to any antifungal or dermatology product portfolio.

Read More

About the Product

Ticonole Gel contains Tioconazole 6.5% w/w, a broad-spectrum antifungal agent used for the treatment of fungal skin infections. It is effective against dermatophytes and yeasts, helping relieve itching, redness, and irritation associated with fungal conditions.

Tioconazole works by disrupting fungal cell membrane synthesis, inhibiting the growth of fungi and leading to their elimination. This targeted action ensures effective clearance of infection and faster symptom relief.

This gel is commonly prescribed for tinea infections, candidal skin infections, and other superficial fungal conditions. Its topical gel formulation allows easy application, quick absorption, and localized action with minimal systemic exposure.

For PCD pharma franchise partners, Ticonole Gel is a high-demand dermatology product, available at the best price for PCD pharma franchise. Its strong prescriber confidence, consistent market demand, and wide usage in skin care make it a valuable addition to any antifungal or dermatology product portfolio.

Common side effects may include mild burning, itching, irritation, or redness at the application site. These effects are usually temporary. Rarely, allergic reactions such as severe itching, swelling, or rash may occur, in which case medical advice should be sought immediately.

Ticonole Gel is indicated for the treatment of vulvovaginal candidiasis (yeast infections) and other susceptible fungal infections as prescribed by a healthcare professional. It helps relieve symptoms such as itching, burning, redness, abnormal discharge, and irritation caused by fungal overgrowth.

Ticonole Gel should be used strictly as directed by a healthcare professional. It is for external or intravaginal use only, depending on medical advice. Avoid contact with eyes and do not use during menstruation unless advised by a doctor. Inform your physician if symptoms persist or worsen.

Store Ticonole Gel in a cool, dry place away from direct heat and sunlight. Keep the tube tightly closed after use and out of reach of children. Do not use the product after the expiry date mentioned on the pack.

Get in Touch

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.

Quick Navigation

1500+ Products

Our Divisions

All Therapeutics

Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.